Troglitazone is a member of the drug class of TZDs (Thiazolidineodiones), which are a class of synthetic PPARγ ligands that improve insulin resistance in target tissues and are used for the treatment of T2D[13]. The gene discussed is PPARG; the disease is Insulin resistance.